SCHEMBL2723343

SCHEMBL2723343

Cc1cccnc1C1(F)CCN(C(=NC2CCN(c3ccccc3)CC2)Nc2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 17/20 0.49
▸ CYP3A4 P08684 1/20 0.39
▸ PHGDH O43175 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2723340 1.00 TRPV1 (0.49) TRPV1CYP3A4PHGDH
SCHEMBL19032342 0.93 TRPV1 (0.55) TRPV1
SCHEMBL19032343 0.93 TRPV1 (0.55) TRPV1
SCHEMBL19946461 0.88 TRPV1 (0.50) TRPV1
SCHEMBL2723345 0.82 TRPV1 (0.42) TRPV1CYP3A4PHGDH
SCHEMBL19946402 0.81 TRPV1 (0.36) TRPV1
SCHEMBL5469316 0.79 TRPV1 (0.55) TRPV1
SCHEMBL5469313 0.79 TRPV1 (0.55) TRPV1
SCHEMBL5464737 0.77 CYP3A4 (0.46) TRPV1CYP3A4PHGDH
SCHEMBL5405805 0.77 TRPV1 (0.61) TRPV1PHGDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12403139-B2 Methods and compositions for prevention and treatment of cardiac hypertrophy UNIVERSITY OF HAWAII (US) 2025-09-02 — — US claimed
US-20240189303-A1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY UNIVERSITY OF HAWAII 2024-06-13 — — US claimed
EP-3393462-B1 COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA UNIV ARIZONA (US) 2023-02-01 — — EP claimed
US-20210069184-A1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY UNIV HAWAII (US) 2021-03-11 — — US claimed
US-20190192508-A1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY UNIV HAWAII (US) 2019-06-27 — — US claimed
US-20190008865-A1 COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2019-01-10 — — US claimed
US-10137123-B2 Methods and compositions for prevention and treatment of cardiac hypertrophy UNIVERSITY OF HAWAII (US) 2018-11-27 — — US claimed
EP-3393462-A1 COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA Arizona Board of Regents on behalf of the University of Arizona (US) 2018-10-31 — — EP claimed
EP-2635281-B1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY UNIV HAWAII (US) 2018-03-14 — — EP claimed
US-20170231982-A1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY UNIVERSITY OF HAWAII 2017-08-17 — — US claimed
WO-2017112693-A1 COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2017-06-29 — — WO claimed
US-20150352105-A1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2015-12-10 — — US claimed
US-9084786-B2 Methods and compositions for prevention and treatmentof cardiac hypertrophy UNIVERSITY OF HAWAII (US) 2015-07-21 — — US claimed
US-20070135423-A1 E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain MERCK SHARP & DOHME LTD. (GB) 2007-06-14 — — US claimed
US-12186314-B2 Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2025-01-07 — — US disclosed
EP-3393462-B1 COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA UNIV ARIZONA (US) 2023-02-01 — — EP disclosed
US-20190008865-A1 COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2019-01-10 — — US disclosed
EP-3348267-A1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY University Of Hawaii (US) 2018-07-18 — — EP disclosed
EP-2635281-A1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY University Of Hawaii (US) 2013-09-11 — — EP disclosed
WO-2012061505-A1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY UNIVERSITY OF HAWAII (US) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135423-A1 E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain OPRL1, HVCN1, TRPV1 TRPV1 3/4885CYP3A4 1886/4885PHGDH 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback